Jeff Behrens, MS, MBA – President and CEO, Board of Directors
Jeff joined Siamab Therapeutics in May 2012. From 2009 to 2012, he served as Senior Director of Business Development & Operations for Edimer Pharmaceuticals, a Third Rock-funded orphan drug company, where he oversaw manufacturing, finance, business development, and academic research collaborations. Prior to Edimer, Jeff worked at Alnylam as Director, Strategic Alliances and at Biogen Idec as co-founder and Head of Business Operations at the Biogen Idec Innovation Incubator. Jeff has an MBA from MIT Sloan and a MS from the joint Harvard/MIT Division of Health Sciences and Technology. Jeff was previously the founder and CEO of The Telluride Group, a Newton, MA based managed services IT provider to the healthcare industry that was sold to mindSHIFT Technologies (funded by Fidelity) in 2003.
Julie DeSander, MS, MBA – Senior Director, Corporate Development
Julie joined Siamab Therapeutics in September 2012, and manages business development, finance, program management, and operations for the company. Prior to Siamab, Julie held various positions in strategy and operations management at Frankel Group, McKinsey & Company, Amgen, and Cerner Corporation. Julie has an MBA from MIT Sloan and a MS from the joint Harvard/MIT Division of Health Sciences and Technology.
Ana Paula Galvao da Silva, PhD – Senior Research Scientist
Ana joined Siamab Therapeutics in June 2013. Prior to joining Siamab, Ana was a postdoc fellow in immunology at Stanford University, and a research scientist at Tocagen and AnaptysBio, where she led the discovery efforts of four monoclonal antibodies in preclinical development. She completed her Bachelors at Federal University of Pernambuco, Brazil, and doctorate at University of São Paulo, Brazil.
Mai Zhang, MD, PhD – Senior Research Scientist
Mai joined Siamab Therapeutics in August 2010. Prior to Siamab, Mai also was a post-doc fellow at Johnson & Johnson, where she worked on histamine H4 receptor and its function on immune diseases, and a research scientist at Nexbio, where she worked on drug discovery projects including a flu therapeutic targeting sialic acid. She received her medical degree in China, and then pursued her PhD degree at the University of California, San Diego in Biomedical Sciences. At UCSD, Mai studied the effects of sialic acid and the receptors in the immune system in Dr. Ajit Varki’s lab.
David Eavarone, PhD – Scientist II
David joined Siamab Therapeutics in November 2014. Prior to joining Siamab, David was a scientist at Visterra Inc. where he played a key role in the development of clinical-stage broad-spectrum therapeutic antibodies for influenza and dengue. Previously, David was a graduate student and postdoctoral researcher in the Health Sciences and Technology program at MIT where he engineered novel chemotherapeutics derived from natural polysaccharides and where he co-invented the ‘Nanocell’ tumor therapy platform, the founding technology for Cerulean Pharma.
Jillian Prendergast, PhD – Scientist I
Jillian joined Siamab Therapeutics in November 2014. Prior to Siamab, Jillian was a postdoctoral researcher at Albert Einstein College of Medicine where she studied a novel protein glycosylation inhibitor. She received her PhD from Johns Hopkins School of Medicine where she investigated singe cell glycolipid metabolism. She also discovered and described a novel glycolipid regulated signaling pathway during her thesis work. Jillian completed her bachelor’s degree at the University of Massachusetts Amherst where she researched the anti-cancer drug, paclitaxel (Taxol), and its production in plants.
Jenna Stein - Office Manager
Jenna joined Siamab Therapeutics in September 2014, and serves as the administrative assistant and office manager. Prior to Siamab, Jenna worked in medical device sales, operations, and customer service. She received a BS in Biology from University of Massachusetts Amherst.
Ajit Varki, MD - Co-Founder, Board of Directors
Dr. Varki is currently the Distinguished Professor of Medicine and Cellular and Molecular Medicine, and Co-Director of the Glycobiology Research and Training Center at UCSD. Dr. Varki received basic training in physiology, medicine, biology, and biochemistry at the Christian Medical College, Vellore, The University of Nebraska, and Washington University in St. Louis. He also has formal training and certification in internal medicine, hematology, and oncology. Dr. Varki’s research interests include the role of sialic acids in viral and bacterial infections, regulation of the immune response, initiation and progression of tumors, and unique aspects of human evolution.
Robert Mashal, MD – Board of Directors
Dr. Mashal is President & CEO of NKT Therapeutics. Before joining NKT Therapeutics, Dr. Mashal was President of Alinea Pharmaceuticals. Prior to that, he was a partner at Boston Millenia Partners, a venture capital firm where he focused on investment opportunities in life sciences. He served as a Director of EpiGenesis Pharmaceuticals, Novalar Pharmaceuticals, GlycoFi, Sapphire Therapeutics, CoApt Systems, Protein Forest, and Cardiomems. He was previously a Program Executive with Vertex Pharmaceuticals, where he led cancer drug development strategy and oversaw pre-clinical/clinical development, marketing, regulatory, and business activities. He was also a member of the Joint Research Committee for the $800 million Vertex-Novartis collaboration. Prior to that, Dr. Mashal served as a consultant at McKinsey & Company, and a faculty member and Attending Physician at Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Harvard Medical School. Dr. Mashal is a diplomate in both internal medicine and oncology. Dr. Mashal is a graduate of Johns Hopkins University and received his M.D. from Johns Hopkins University School of Medicine.
Sundar Subramaniam, MS, MBA – Board of Directors
Sundar Subramaniam is Chairman of IBCC, whose holdings include Cambridge Technology Enterprises, Knome, MTPV, Cambridge Energy Resources, ThriveHive and DNSstuff. He is Chairman of Knome and Sialix and General Partner at Higher Moment Capital. He previously served as Chairman of I-Cube, C-bridge, Open Environment Corporation, and OneWave – all of which completed IPO’s and Answerfriend (Inquira, acq Oracle), WorldStreet (acq Thomson Reuters) and Integrated Computing Engines (acq Media100), director of DNSstuff (acq Solarwinds) and Managing Partner of Cambridge Samsung Partners, a Venture Capital firm.
Brad Curley, BS, CPA - Board of Directors
Brad Curley is a member of Boston Harbor Angels and an adjunct professor at Boston College. He was with KPMG LLP for more than 25 years providing services to clients in many industries. Brad was Partner in Charge of KPMG’s New England Area Internal Audit, Risk and Compliance Services practice and also served as the Firm’s Advisory Services practice leader for Northeast Area middle market accounts. He is a member of Board Leaders, the Corporate Directors Group and the National Association of Corporate Directors.